The site is undergoing maintenance on
Friday, September 11, 2026, 1:00 - 9:00 am (KST).
If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
See More
The site is undergoing maintenance on
Friday, September 11, 2026, 1:00 - 9:00 am (KST).
If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
See MoreThe site is undergoing maintenance on
Friday, September 11, 2026, 1:00 - 9:00 am (KST)
.If you encounter problems while ordering, please contact us at BDBCustomerService@bd.com
Looks like you're visiting us from {countryName}.
Would you like to stay on the current location or be switched to your location?
Expression of GM-CSF by stimulated human peripheral blood mononuclear cells (PBMC). Ficoll™-separated human PBMC were stimulated with Purified NA/LE Mouse Anti-Human CD3 (1 µg/ml final concentration; Cat. No. 555329), recombinant human IL-2 (10 ng/ml final concentration; Cat. No. 554603) and recombinant human IL-4 (10 ng/ml final concentration; Cat. No. 554605) for 2 days. The cells were subsequently cultured in medium containing recombinant human IL-2 and recombinant human IL-4 for 3 days. Finally, the cells were harvested and stimulated for 6 hours with PMA (50 ng/ml final concentration; Sigma, Cat. #P-8139) and calcium ionophore A23187 (250 ng/ml final concentration; Sigma, Cat. #C-9275) in the presence of BD GolgiStop™ (2 µM final concentration; Cat. No. 554724). The cells were harvested, stained with PE-Cy™5 Mouse Anti-Human CD4 (Cat. No. 555348), fixed, permeabilized, and subsequently stained with 0.25 µg of PE Rat anti-Human GM-CSF (Cat. No. 554507) antibody by using the intracellular staining protocol (see Left panel). To demonstrate specificity of staining, the binding of PE Rat Anti-Human GM-CSF was blocked by preincubation of the antibody conjugate with recombinant human GM-CSF (0.1 µg; Cat. No. 550068; see Center panel) and by preincubation of the fixed/permeabilized cells with Purified Rat Anti-Human GM-CSF (5 µg; Cat. No. 554503; see Right panel) prior to staining. The quadrant markers for the bivariate dot plot were set based on the autofluorescence control and verified using the ligand-blocking and unlabeled antibody blocking controls.
Expression of GM-CSF by stimulated human peripheral blood mononuclear cells (PBMC). Ficoll™-separated human PBMC were stimulated with Purified NA/LE Mouse Anti-Human CD3 (1 µg/ml final concentration; Cat. No. 555329), recombinant human IL-2 (10 ng/ml final concentration; Cat. No. 554603) and recombinant human IL-4 (10 ng/ml final concentration; Cat. No. 554605) for 2 days. The cells were subsequently cultured in medium containing recombinant human IL-2 and recombinant human IL-4 for 3 days. Finally, the cells were harvested and stimulated for 6 hours with PMA (50 ng/ml final concentration; Sigma, Cat. #P-8139) and calcium ionophore A23187 (250 ng/ml final concentration; Sigma, Cat. #C-9275) in the presence of BD GolgiStop™ (2 µM final concentration; Cat. No. 554724). The cells were harvested, stained with PE-Cy™5 Mouse Anti-Human CD4 (Cat. No. 555348), fixed, permeabilized, and subsequently stained with 0.25 µg of PE Rat anti-Human GM-CSF (Cat. No. 554507) antibody by using the intracellular staining protocol (see Left panel). To demonstrate specificity of staining, the binding of PE Rat Anti-Human GM-CSF was blocked by preincubation of the antibody conjugate with recombinant human GM-CSF (0.1 µg; Cat. No. 550068; see Center panel) and by preincubation of the fixed/permeabilized cells with Purified Rat Anti-Human GM-CSF (5 µg; Cat. No. 554503; see Right panel) prior to staining. The quadrant markers for the bivariate dot plot were set based on the autofluorescence control and verified using the ligand-blocking and unlabeled antibody blocking controls.
Expression of GM-CSF by stimulated human peripheral blood mononuclear cells (PBMC). Ficoll™-separated human PBMC were stimulated with Purified NA/LE Mouse Anti-Human CD3 (1 µg/ml final concentration; Cat. No. 555329), recombinant human IL-2 (10 ng/ml final concentration; Cat. No. 554603) and recombinant human IL-4 (10 ng/ml final concentration; Cat. No. 554605) for 2 days. The cells were subsequently cultured in medium containing recombinant human IL-2 and recombinant human IL-4 for 3 days. Finally, the cells were harvested and stimulated for 6 hours with PMA (50 ng/ml final concentration; Sigma, Cat. #P-8139) and calcium ionophore A23187 (250 ng/ml final concentration; Sigma, Cat. #C-9275) in the presence of BD GolgiStop™ (2 µM final concentration; Cat. No. 554724). The cells were harvested, stained with PE-Cy™5 Mouse Anti-Human CD4 (Cat. No. 555348), fixed, permeabilized, and subsequently stained with 0.25 µg of PE Rat anti-Human GM-CSF (Cat. No. 554507) antibody by using the intracellular staining protocol (see Left panel). To demonstrate specificity of staining, the binding of PE Rat Anti-Human GM-CSF was blocked by preincubation of the antibody conjugate with recombinant human GM-CSF (0.1 µg; Cat. No. 550068; see Center panel) and by preincubation of the fixed/permeabilized cells with Purified Rat Anti-Human GM-CSF (5 µg; Cat. No. 554503; see Right panel) prior to staining. The quadrant markers for the bivariate dot plot were set based on the autofluorescence control and verified using the ligand-blocking and unlabeled antibody blocking controls.
Expression of GM-CSF by stimulated human peripheral blood mononuclear cells (PBMC). Ficoll™-separated human PBMC were stimulated with Purified NA/LE Mouse Anti-Human CD3 (1 µg/ml final concentration; Cat. No. 555329), recombinant human IL-2 (10 ng/ml final concentration; Cat. No. 554603) and recombinant human IL-4 (10 ng/ml final concentration; Cat. No. 554605) for 2 days. The cells were subsequently cultured in medium containing recombinant human IL-2 and recombinant human IL-4 for 3 days. Finally, the cells were harvested and stimulated for 6 hours with PMA (50 ng/ml final concentration; Sigma, Cat. #P-8139) and calcium ionophore A23187 (250 ng/ml final concentration; Sigma, Cat. #C-9275) in the presence of BD GolgiStop™ (2 µM final concentration; Cat. No. 554724). The cells were harvested, stained with PE-Cy™5 Mouse Anti-Human CD4 (Cat. No. 555348), fixed, permeabilized, and subsequently stained with 0.25 µg of PE Rat anti-Human GM-CSF (Cat. No. 554507) antibody by using the intracellular staining protocol (see Left panel). To demonstrate specificity of staining, the binding of PE Rat Anti-Human GM-CSF was blocked by preincubation of the antibody conjugate with recombinant human GM-CSF (0.1 µg; Cat. No. 550068; see Center panel) and by preincubation of the fixed/permeabilized cells with Purified Rat Anti-Human GM-CSF (5 µg; Cat. No. 554503; see Right panel) prior to staining. The quadrant markers for the bivariate dot plot were set based on the autofluorescence control and verified using the ligand-blocking and unlabeled antibody blocking controls.
Expression of GM-CSF by stimulated human peripheral blood mononuclear cells (PBMC). Ficoll™-separated human PBMC were stimulated with Purified NA/LE Mouse Anti-Human CD3 (1 µg/ml final concentration; Cat. No. 555329), recombinant human IL-2 (10 ng/ml final concentration; Cat. No. 554603) and recombinant human IL-4 (10 ng/ml final concentration; Cat. No. 554605) for 2 days. The cells were subsequently cultured in medium containing recombinant human IL-2 and recombinant human IL-4 for 3 days. Finally, the cells were harvested and stimulated for 6 hours with PMA (50 ng/ml final concentration; Sigma, Cat. #P-8139) and calcium ionophore A23187 (250 ng/ml final concentration; Sigma, Cat. #C-9275) in the presence of BD GolgiStop™ (2 µM final concentration; Cat. No. 554724). The cells were harvested, stained with PE-Cy™5 Mouse Anti-Human CD4 (Cat. No. 555348), fixed, permeabilized, and subsequently stained with 0.25 µg of PE Rat anti-Human GM-CSF (Cat. No. 554507) antibody by using the intracellular staining protocol (see Left panel). To demonstrate specificity of staining, the binding of PE Rat Anti-Human GM-CSF was blocked by preincubation of the antibody conjugate with recombinant human GM-CSF (0.1 µg; Cat. No. 550068; see Center panel) and by preincubation of the fixed/permeabilized cells with Purified Rat Anti-Human GM-CSF (5 µg; Cat. No. 554503; see Right panel) prior to staining. The quadrant markers for the bivariate dot plot were set based on the autofluorescence control and verified using the ligand-blocking and unlabeled antibody blocking controls.
Expression of GM-CSF by stimulated human peripheral blood mononuclear cells (PBMC). Ficoll™-separated human PBMC were stimulated with Purified NA/LE Mouse Anti-Human CD3 (1 µg/ml final concentration; Cat. No. 555329), recombinant human IL-2 (10 ng/ml final concentration; Cat. No. 554603) and recombinant human IL-4 (10 ng/ml final concentration; Cat. No. 554605) for 2 days. The cells were subsequently cultured in medium containing recombinant human IL-2 and recombinant human IL-4 for 3 days. Finally, the cells were harvested and stimulated for 6 hours with PMA (50 ng/ml final concentration; Sigma, Cat. #P-8139) and calcium ionophore A23187 (250 ng/ml final concentration; Sigma, Cat. #C-9275) in the presence of BD GolgiStop™ (2 µM final concentration; Cat. No. 554724). The cells were harvested, stained with PE-Cy™5 Mouse Anti-Human CD4 (Cat. No. 555348), fixed, permeabilized, and subsequently stained with 0.25 µg of PE Rat anti-Human GM-CSF (Cat. No. 554507) antibody by using the intracellular staining protocol (see Left panel). To demonstrate specificity of staining, the binding of PE Rat Anti-Human GM-CSF was blocked by preincubation of the antibody conjugate with recombinant human GM-CSF (0.1 µg; Cat. No. 550068; see Center panel) and by preincubation of the fixed/permeabilized cells with Purified Rat Anti-Human GM-CSF (5 µg; Cat. No. 554503; see Right panel) prior to staining. The quadrant markers for the bivariate dot plot were set based on the autofluorescence control and verified using the ligand-blocking and unlabeled antibody blocking controls.
Becton, Dickinson and Company의 명시적인 서면 승인 없이는 사용 하실 수 없습니다.
Blocking Control for Intracellular Staining: The purified BVD2-21C11 antibody (Cat. No. 554503) can be used as a blocking control to demonstrate specificity of human GM-CSF staining by the PE-BVD2-21C11 (Cat. No. 554507). To perform this control, the fixed/permeabilized cells (~ 1 million) can be incubated with 1 - 10 µg of unlabeled BVD2-21C11 antibody (Cat. No. 554503) for 20 minutes at 4°C, prior to staining with PE-BVD2-21C11 antibody (eg, 0.1 - 0.5 µg mAb/ 1 million cells). The intracellular cytokine staining technique and use of blocking controls are described in detail by C. Prussin and D. Metcalfe. For specific methodology, please visit the protocols section under "Cytokines (Intracellular Staining)" at our website: http://www.bdbiosciences.com/us/s/resources.
ELISA Detection: The biotinylated BVD2-21C11 antibody, Cat. No. 554505, is useful as a detection antibody for a sandwich ELISA for measuring human GM-CSF protein levels. Biotinylated BVD2-21C11 antibody can be paired with the purified BVD2-23B6 antibody (Cat. No. 554502) as the capture antibody, with recombinant human GM-CSF (Cat. No. 550068) as the standard. For specific methodology please visit the protocols sections or the chapter on ELISA in the Immune Function Handbook, both of which are posted on our web site, www.bdbiosciences.com. This ELISA pair is recommended primarily for measuring cytokine from experimental cell culture systems. Note: For testing GM-CSF in serum or plasma, our BD OptEIA™ ELISA Set (Cat. No. 555126) is recommended.
IP: The purified BVD2-21C11 antibody has been reported to be useful for immunoprecipitation studies. Please note that this application is not routinely tested at BD Biosciences Pharmingen.
The BVD2-21C11 monoclonal antibody specifically binds to human Granulocyte/Macrophage - Colony Stimulating Factor (GM-CSF). Human GM-CSF is encoded by the CSF2 gene and is also known as Colony Stimulating Factor 2. GM-CSF is produced by activated T lymphocytes, macrophages, endothelial cells, fibroblasts, stromal cells and other cell types including B lymphocytes, mast cells, eosinophils, and osteoblasts. GM-CSF stimulates the survival, proliferation and/or differentiation of various cell types including neutrophils, eosinophils, macrophages, dendritic cells, megakaryocytes, erythroid cells, endothelial cells and their precursors. The immunogen used to generate the BVD2-21C11 hybridoma was recombinant human GM-CSF. The BVD2-21C11 antibody has been reported to crossreact with GM-CSF from the rhesus monkey. BVD2-21C11 is a neutralizing antibody.
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.